HomeCompareAFGVY vs PFE

AFGVY vs PFE: Dividend Comparison 2026

AFGVY yields 87.34% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AFGVY wins by $2.24M in total portfolio value
10 years
AFGVY
AFGVY
● Live price
87.34%
Share price
$2.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.29M
Annual income
$703,728.77
Full AFGVY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AFGVY vs PFE

📍 AFGVY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAFGVYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AFGVY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AFGVY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AFGVY
Annual income on $10K today (after 15% tax)
$7,423.58/yr
After 10yr DRIP, annual income (after tax)
$598,169.45/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, AFGVY beats the other by $575,849.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AFGVY + PFE for your $10,000?

AFGVY: 50%PFE: 50%
100% PFE50/50100% AFGVY
Portfolio after 10yr
$1.17M
Annual income
$364,993.75/yr
Blended yield
31.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AFGVY
No analyst data
Altman Z
2.5
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AFGVY buys
0
PFE buys
0
No recent congressional trades found for AFGVY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAFGVYPFE
Forward yield87.34%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$2.29M$49.6K
Annual income after 10y$703,728.77$26,258.71
Total dividends collected$2.01M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AFGVY vs PFE ($10,000, DRIP)

YearAFGVY PortfolioAFGVY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$19,434$8,733.62$9,153$693.39+$10.3KAFGVY
2$36,656$15,862.24$8,593$849.25+$28.1KAFGVY
3$67,185$27,962.41$8,336$1,066.78+$58.8KAFGVY
4$119,785$47,897.48$8,437$1,384.80+$111.3KAFGVY
5$207,981$79,810.81$9,013$1,875.40+$199.0KAFGVY
6$352,048$129,508.63$10,306$2,680.72+$341.7KAFGVY
7$581,569$204,877.25$12,820$4,101.38+$568.7KAFGVY
8$938,586$316,307.17$17,673$6,826.70+$920.9KAFGVY
9$1,481,374$477,087.66$27,543$12,591.86+$1.45MAFGVY
10$2,288,799$703,728.77$49,560$26,258.71+$2.24MAFGVY

AFGVY vs PFE: Complete Analysis 2026

AFGVYStock

Agfa-Gevaert NV develops, produces, and distributes various analog and digital imaging systems, and IT solutions worldwide. The company's Offset Solutions segment provides commercial, newspaper, and packaging printers; integrated prepress and printing solutions, including computer-to-plate systems using digital offset printing plates, pressroom supplies, and software for workflow optimization, color management, screening, and print standardization; and security printing software solutions. Its Radiology Solutions segment offers analog and digital imaging technology for diagnostic imaging market to meet the needs of specialized clinicians in hospitals and imaging centers; and X-ray film, hardcopy film and printers, digital radiography equipment, and image processing software. The company's Healthcare IT segment provides picture archiving and communication systems; hospital information system and clinical information systems; and integrated care solutions. Its Digital Print & Chemicals segment offers inkjet printers for sign and display printing companies; inkjet inks and fluids for industrial inkjet applications, such as signs, posters and displays, promotional materials, packaging, leather goods, laminated flooring, and decorative materials, as well as for printed electronics industry; membranes to the hydrogen production industry, as well as for printable synthetic papers; UV-curable and water based inks for various industrial applications. This segment also provides films for micrography, non-destructive testing, aerial photography and printed circuit board production; specialty foils for security documents and print media; and conductive polymers and materials for the production of high-security ID documents. The company sells its products through its own sales organization, as well as through a network of agents and representatives. Agfa-Gevaert NV was founded in 1867 and is headquartered in Mortsel, Belgium.

Full AFGVY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AFGVY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AFGVY vs SCHDAFGVY vs JEPIAFGVY vs OAFGVY vs KOAFGVY vs MAINAFGVY vs JNJAFGVY vs MRKAFGVY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.